Tag: leukemia

1. Patients with relapsed or remitting chronic lymphocytic leukemia (CLL) treated with venetoclax-rituximab had a greater 2-year progression-free survival rate compared to bendamustine-rituximab treated patients. 2. Progression-free survival rates were greater for venetoclax-rituximab patients in almost all subgroup analysis, including patients with chromosome 17p deletion. Evidence Rating Level: 1 (Excellent) Study Rundown: Curative...
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia BCL2 is an anti-apoptotic protein that allows chronic lymphocytic leukemia cells to survive and a promising pharmacologic target for relapsed chronic lymphocytic leukemia. Previously, drugs like navitoclax showed efficacy to the same target but cross-reacted with other proteins and caused thrombocytopenia....
  1. The compound ICG-001 sensitized chemoresistant leukemia-initiating cells (LICs) to Imatinib (IM) and inhibited their ability to survive and proliferate. 2. In mice, combined treatment of ICG-001 with Nilotinib led to reduced cancer cell growth and improved survival. Evidence Rating Level: 2 (Good)            Study Rundown: Chronic myelogenous...
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) is a spectrum of indolent malignant blood disorders characterized by progressive immune suppression and myelosuppression. While many patients are observed instead of given active therapy given low-grade disease, CLL is incurable and...
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia BRAF V600E has been identified as the genetic lesion responsible for the development of hairy-cell leukemia.  In this study, researchers conducted two phase-2, single-group, multicenter trials looking at the effectiveness and safety of oral vemurafenib (a BRAF inhibitor) in patients with...
1. Mice harboring tumors with translocations of the mixed lineage leukemia (MLL) gene showed decreased tumor size and increased survival times when treated with a pharmacologic inhibitor of a menin-MLL interaction. 2. Menin-MLL inhibitors selectively killed colony forming cells from human leukemia patients with MLL translocations.  Evidence Rating Level:...
Originally published by Harvard Health. What Is It? Acute myeloid leukemia (AML) is a type of leukemia. It is also called acute myelogenous leukemia, acute myeloblastic leukemia, acute myelocytic leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia. Leukemia is a cancer of the blood and bone marrow. Bone marrow is the soft, inner...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Goal-Directed Resuscitation for Patients with Early Septic Shock The monumental Rivers et al publication laid forth the groundwork for early goal-directed therapy (EGDT) for sepsis management, a framework that has been embraced...
1. Ibrutinib was superior to ofatumumab in a head-to-head trial in patients who have failed initial therapy for chronic lymphoid leukemia (CLL) and small lymphocytic leukemia (SLL).  2. The benefit of progression-free survival for those on ibrutinib was preserved across all subgroups including common poor prognostic indicators (e.g. specific cytogenetic...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia Idelalisib, a phosphatidylinositol 3-kinase inhibitor, showed promising clinical activity and low toxicity during treatment of relapsed CLL in phase 1 studies in...